Cisplatin and Its Analogues in Advanced Breast Cancer Treatment
Author Information
Author(s): I.E. Smith, D.C. Talbot
Primary Institution: Royal Marsden Hospital
Hypothesis
Cisplatin may be more effective as first-line chemotherapy for advanced breast cancer than previously thought.
Conclusion
Cisplatin shows significant activity as first-line treatment for advanced breast cancer, but its toxicity limits its use.
Supporting Evidence
- Cisplatin has shown a response rate of 54% in previously untreated patients.
- Combination therapies with cisplatin have achieved response rates as high as 68%.
- High doses of cisplatin can lead to significant toxicity, including nausea and renal issues.
Takeaway
Cisplatin can help treat advanced breast cancer, but it can also make people very sick.
Methodology
Review of clinical trials and studies on cisplatin and its analogues in breast cancer treatment.
Potential Biases
Potential bias due to the lack of randomization in many studies.
Limitations
Many studies are uncontrolled and involve small patient numbers.
Participant Demographics
Patients with advanced breast cancer, some previously treated with chemotherapy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website